Highlights

  • All dogs in the trial successfully received the full SIRT6-based gene therapy administration.
  • No adverse events were observed, indicating the therapy was well tolerated during dosing.
  • First efficacy data is expected in mid-to-late January 2026, including blood and muscle analyses.

Genflow Biosciences Plc (LSE:GENF), a biotechnology company developing gene therapies targeting healthspan, has completed the dosing phase of its ongoing canine trial. All enrolled dogs received the full administration of the investigational SIRT6-based therapy. During this phase, no adverse events were reported, and no serious, moderate, or minor side effects were observed.

Safety and Tolerability Profile
The absence of adverse events suggests a favorable safety and tolerability profile for the therapy during the initial phase. The study is being conducted as a blinded clinical trial, so efficacy outcomes cannot yet be assessed.

Upcoming Efficacy Assessments
Genflow plans to conduct the first efficacy readout in mid-to-late January 2026. This evaluation will include blood analyses and muscle biopsies to examine potential therapeutic effects related to sarcopenia, overall healthspan, and lifespan-associated biomarkers.

The dogs will continue to be monitored over a total period of 180 days. A second efficacy assessment is planned at the six-month mark, with results expected between June and July 2026. This assessment will focus on evaluating the durability and longer-term effects of the therapy.

Next Steps for Data Analysis
Following the efficacy analyses, Genflow intends to resume discussions with several animal health companies, including parties currently engaged under confidentiality and data access agreements, to explore potential early-stage licensing arrangements.

Share Price Snapshot
GENF was trading 8.57% higher at GBX 1.90 per share as of 16 December 2025.